Rongrong Zheng

Years Active: 2024-2024
Publications (10 Years): 1

This page only lists publications with an associated author ORCID identifier.

Publications

Jianjun Qin, Liyan Xue, Anlin Hao, Xiaofeng Guo, Tao Jiang, Yunfeng Ni, Shuoyan Liu, Yujie Chen, Hongjing Jiang, Chen Zhang, Mingqiang Kang, Jihong Lin, Hecheng Li, Chengqiang Li, Hui Tian, Lin Li, Junke Fu, Yong Zhang, Jianqun Ma, Xiaoyuan Wang, Maoyong Fu, Hao Yang, Zhaoyang Yang, Yongtao Han, Longqi Chen, Lijie Tan, Tianyang Dai, Yongde Liao, Weiguo Zhang, Bin Li, Qixun Chen, Shiping Guo, Yu Qi, Li Wei, Zhi-Gang Li, Ziqiang Tian, Xiaozheng Kang, Ruixiang Zhang, Yong Li, Zhen Wang, Xiankai Chen, Zhiguo Hou, Rongrong Zheng, Wenqing Zhu, Jie He, Yin Li
Neoadjuvant chemotherapy with or without camrelizumab in resectable esophageal squamous cell carcinoma: the randomized phase 3 ESCORT-NEO/NCCES01 trial. Nature medicine (2024)

Rongrong Zheng.css-eqlu8i{font-size:small;padding-left:4px;}